Literature DB >> 7384082

The LNCaP cell line--a new model for studies on human prostatic carcinoma.

J S Horoszewicz, S S Leong, T M Chu, Z L Wajsman, M Friedman, L Papsidero, U Kim, L S Chai, S Kakati, S K Arya, A A Sandberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7384082

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN： 0361-7742


× No keyword cloud information.
  168 in total

1.  Evidence of chromosomal instability in prostate cancer determined by spectral karyotyping (SKY) and interphase fish analysis.

Authors:  B Beheshti; P C Park; J M Sweet; J Trachtenberg; M A Jewett; J A Squire
Journal:  Neoplasia       Date:  2001 Jan-Feb       Impact factor: 5.715

2.  Identification of a high frequency of chromosomal rearrangements in the centromeric regions of prostate cancer cell lines by sequential giemsa banding and spectral karyotyping.

Authors:  B Beheshti; J Karaskova; P C Park; J A Squire; B G Beatty
Journal:  Mol Diagn       Date:  2000-03

Review 3.  Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer.

Authors:  Martin E Gleave; Toby Zellweger; Kim Chi; Hideaki Miyake; Satoshi Kiyama; Laura July; Simon Leung
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

4.  Androgen mediated translational and postranslational regulation of IGFBP-2 in androgen-sensitive LNCaP human prostate cancer cells.

Authors:  David J Degraff; Adam A Aguiar; Qian Chen; Lisa K Adams; B Jill Williams; Robert A Sikes
Journal:  Am J Transl Res       Date:  2010-03-06       Impact factor: 4.060

Review 5.  The human prostatic carcinoma cell line LNCaP and its derivatives. An overview.

Authors:  G J van Steenbrugge; M Groen; J W van Dongen; J Bolt; H van der Korput; J Trapman; M Hasenson; J Horoszewicz
Journal:  Urol Res       Date:  1989

Review 6.  Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death.

Authors:  Simeng Wen; Yuanjie Niu; Soo Ok Lee; Chawnshang Chang
Journal:  Cancer Treat Rev       Date:  2013-08-07       Impact factor: 12.111

7.  Transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1 for targeting prostate tumors.

Authors:  Cleo Y F Lee; Luke X X Bu; Arrigo DeBenedetti; B Jill Williams; Paul S Rennie; William W G Jia
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

8.  A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49.

Authors:  Lawrence D True; Kent Buhler; Janna Quinn; Emily Williams; Peter S Nelson; Nigel Clegg; Jill A Macoska; Thomas Norwood; Alvin Liu; William Ellis; Paul Lange; Robert Vessella
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

9.  Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate.

Authors:  D Samid; S Shack; C E Myers
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

10.  Characterization of prostate-tissue-directed monoclonal antibody, alpha-Pro 13.

Authors:  K S Webb; D F Paulson; S F Parks; F L Tuck; P J Walther; J L Ware
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.